Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019

Martin C. Mahoney 1,*, Cheryl Rivard 1,†, Heather L. Kimmel 2, Hoda T. Hammad 3, Eva Sharma 4, Michael J. Halenar 4, Jim Sargent 5, K. Michael Cummings 6, Ray Niaura 7, Maciej L. Goniewicz 1, Maansi Bansal-Travers 1, Dorothy Hatsukami 8, Diann Gaalema 9, Geoffrey Fong 10, Shannon Gravely 10, Carol H. Christensen 3, Ryan Haskins 3, Marushka L. Silveira 2,11, Carlos Blanco 2, Wilson Compton 2, Cassandra A. Stanton 3 and Andrew Hyland 1

1 Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA; martin.mahoney@roswellpark.org (M.C.M.); maciej.goniewicz@roswellpark.org (M.L.G.); maansi.travers@roswellpark.org (M.B-T.); andrew.hyland@roswellpark.org (A.H.)
2 National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA; heather.kimmel@nih.gov (H.L.K.); marushka.silveira@nih.gov (M.L.S.); carlos.blanco2@nih.gov (C.B.); wcompton@nida.nih.gov (W.C.)
3 Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA; hoda.hammad@fda.hhs.gov (H.T.H.); carol.christensen@fda.hhs.gov (C.H.C.); ryan.haskins@fda.hhs.gov (R.H.)
4 Westat, Rockville, MD 20850, USA; evasharma@westat.com (E.S.); michaelhalenar@westat.com (M.J.H.); cassandra.stanton@westat.com (C.A.S.)
5 The C. Everett Koop Institute at Dartmouth, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA; james.d.sargent@dartmouth.edu
6 Medical University of South Carolina, Charleston, SC 29425, USA; cummingk@musc.edu
7 NYU School of Global Public Health, New York, NY 10003, USA; m54@nyu.edu
8 University of Minnesota, Minneapolis, MN 55414, USA; hatsu01@umn.edu
9 University of Vermont, Burlington, VT 05404, USA; diann.gaalema@uvm.edu
10 University of Waterloo, Waterloo, ON N2L 3G1, Canada; geoffrey.fong@uwaterloo.ca (G.F.); shannon.gravely@uwatwaterloo.ca (S.G.)
11 Kelly Government Solutions, Troy, MI 48084, USA
* Correspondence: cheryl.rivard@roswellpark.org; Tel.: +1-716-845-3321

Abstract: Background: Prior studies have not clearly established risk of cardiovascular disease (CVD) among smokers who switch to exclusive use of electronic nicotine delivery systems (ENDS). We compared cardiovascular disease incidence in combustible-tobacco users, those who transitioned to ENDS use, and those who quit tobacco with never tobacco users. Methods: This prospective cohort study analyzes five waves of Population Assessment of Tobacco and Health (PATH) Study data, Wave 1 (2013–2014) through Wave 5 (2018–2019). Cardiovascular disease (CVD) incidence was captured over three intervals (Waves 1 to 3, Waves 2 to 4, and Waves 3 to 5). Participants were adults (40+ years old) without a history of CVD for the first two waves of any interval. Change in tobacco use status, from exclusive past 30 day use of any combustible-tobacco product to either exclusive past 30 day ENDS use, dual past 30 day use of ENDS and combustible-tobacco, or no past 30 day use of any tobacco, between the first two waves of an interval was used to predict onset of CVD between the second and third waves in the interval. CVD incidence was defined as a new self-report of being told by a health professional that they had congestive heart failure, stroke, or a myocardial infarction. Generalized estimating equation (GEE) analyses combined 10,548 observations across intervals from 7820 eligible respondents. Results: Overall, there were 191 observations of CVD among 10,548 total observations (1.7%, standard error (SE) = 0.2), with 40 among 3014 never users of tobacco (1.5%, SE = 0.3). In multivariable models, CVD incidence was not significantly different for any tobacco user groups compared to never users. There were 126 observations of CVD among 6263 continuing exclusive combustible-tobacco users (adjusted odds ratio [AOR] = 1.44; 95% confidence interval (CI))
0.87–2.39), 15 observations of CVD among 565 who transitioned to dual use (AOR = 1.85; 0.78–4.37), and 10 observations of CVD among 654 who quit using tobacco (AOR = 1.18; 0.33–4.26). There were no observations of CVD among 53 who transitioned to exclusive ENDS use. Conclusions: This study found no difference in CVD incidence by tobacco status over three 3 year intervals, even for tobacco quitters. It is possible that additional waves of PATH Study data, combined with information from other large longitudinal cohorts with careful tracking of ENDS use patterns may help to further clarify this relationship.

Keywords: tobacco use; cardiovascular disease; health survey; electronic nicotine delivery systems (ENDS); electronic cigarette

1. Introduction

Since the 1964 Advisory Report to the Surgeon General on smoking and health, documenting the harms caused by smoking and other tobacco products has been a recurring theme of subsequent reports issued by the Surgeon General [1,2]. The 2014 Surgeon General’s report stated that cigarette smokers have a 2–4-fold higher risk of cardiovascular diseases (CVDs) (e.g., coronary heart disease, myocardial infarction (MI), hypertension, congestive heart failure (CHF) and stroke) compared to non-smokers [1–3]. Moreover, ischemic events within the heart (e.g., MI) and brain (e.g., stroke) together accounted for ~28% of all deaths in the United States in 2016 and 2017 [4]. In addition to fatal and non-fatal acute cardiovascular events, smoking contributes to accelerated rates of atherosclerosis and sudden death [2]. Cessation of smoking reduces the risk of coronary events fairly rapidly, so that within three years of quitting, the average risk level is similar to that of someone who never smoked [5].

The mechanisms underlying increased risks of cardiovascular events, which are best characterized among cigarette smokers, but extend to users of other combusted tobacco products, are multifactorial and include exposures to harmful constituents of tobacco smoke and interactions with various physiologic processes. Tobacco smoke contains oxidizing chemicals, nicotine, carbon monoxide (CO), volatile organic compounds, particulates and heavy metals. The oxidizing compounds contribute to lipid formation, endovascular deposition and oxidative stress within blood vessels. Exposure to nicotine results in hemodynamic changes including increased blood pressure and heart rate, resulting in increased cardiac demand, while the vasoconstrictive effects of nicotine simultaneously decrease blood flow, resulting in reduced oxygen supply [1,2,6]. Nicotine also results in arrhythmogenesis and an increased risk of a fatal cardiac event [2,6]. CO reduces oxygen delivery such that increased oxygen demand is met with decreased availability [1,2]. Moreover, tobacco smoking contributes to endothelial dysfunction, hypercoagulable state/thrombosis, inflammation, insulin resistance (thereby increasing risk of diabetes in smokers), hyperlipidemia (smoking decreases high-density lipoprotein [HDL] levels and oxidizes low-density lipoprotein (LDL), leading to endovascular deposition and increased inflammation and atherosclerosis, including within coronary and cerebral vessels) [1,2,6].

Because electronic nicotine delivery systems (ENDS) are relatively new products in the marketplace, there are few longitudinal studies that have been able to explore the association between ENDS use and cardiovascular disease risk. Most of the epidemiologic studies on ENDS and CVD risks are based on cross-sectional designs using prevalence outcomes [7–9]. Further complicating matters is the observation that most ENDS users are former smokers, so adjusting for one’s prior smoking history is challenging.

Since many of the harms of smoking are related to the direct and indirect effects of combustion, some evidence suggests that ENDS do not appear to have major short-term health effects [10], which offers support for a “harm-reduction” strategy of switching from combusted tobacco to ENDS [7,8]. However, laboratory studies point to a potential increase in oxidative stress and changes in heart rate variability resulting from ENDS
use [9,11], both of which are associated with increased cardiovascular risk [9,12]. While some of this cardiovascular risk has been attributed to the physiologic effects of nicotine, the explanation for increased oxidative stress is unclear but could be related to lipid peroxidation as evidenced by decreases in nitric oxide and increases in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and 8-iso-prostaglandin F2α noted among users of ENDS [9,11].

Since existing studies have not clearly established whether the risk of CVD changes when smokers switch to exclusive use of ENDS, we seek to address this gap using longitudinal Population Assessment of Tobacco and Health (PATH) Study data from Waves 1 to 5 (2013/14–2018/19) to compare CVD incidence among adults (age 40+ years who were either exclusive combustible-tobacco users or never users of tobacco at baseline) grouped into: (1) exclusive combustible-tobacco (including cigarettes, traditional cigars, cigarillos, filtered cigars, pipe tobacco, and hookah) users who remain exclusive combustible-tobacco users, (2) exclusive combustible-tobacco users who transitioned to exclusive ENDS use, (3) exclusive combustible-tobacco users who transitioned to dual use of ENDS and combustible-tobacco, (4) exclusive combustible-tobacco users who quit using tobacco, and (5) never users of tobacco.

2. Materials and Methods

The PATH Study is an ongoing, nationally representative, longitudinal cohort study of adults and youth in the United States (U.S.). The study uses audio computer-assisted self-interviews (ACASI), available in English and Spanish, to collect information on tobacco use patterns and associated health behaviors. The PATH Study recruitment for the Wave 1 Cohort employed a stratified address-based, area-probability sampling design that oversampled adult tobacco users, young adults (18 to 24 years), and African American adults. An in-person screener was used at Wave 1 (W1) to randomly select youths and adults from households for participation in the study. The total unweighted cumulative attrition rate among the W1 sample was 16% at Wave 2 (W2), 21% at Wave 3 (W3), 27% at Wave 4 (W4), and 30% at Wave 5 (W5). Differences in the number of completed interviews between Wave 1 and subsequent waves reflect respondent attrition (e.g., non-response and mortality). An analysis of non-response bias from attrition from W1 to W4 of the PATH Study (available in the PATH Study Restricted Use Files User Guide [12]) concluded “little if any non-response bias” among adults.

Full-sample and replicate weights were created to adjust for the complex sample design (e.g., oversampling of specified groups) and non-response. Weighted estimates represent the resident population of the U.S. who were in the civilian, non-institutionalized population (CNP) at W1 and W5. All-wave weights were assigned to W5 respondents in the W1 cohort, who also participated in W2, W3, and W4. Further details regarding the PATH Study design and methods for the W1 cohort are published elsewhere [13–15]. The analyses presented here used the Restricted Use Files (RUF). Missing data on age were imputed as described in the PATH Study Restricted Use Files User Guide, and details on interview procedures, questionnaires, sampling, weighting, response rates, and accessing the data are described in the PATH Study Restricted Use Files User Guide. The study was conducted by Westat and approved by the Westat Institutional Review Board. All respondents ages 18 and older provided informed consent.

2.1. Measures

2.1.1. Tobacco Use

At each wave, respondents were asked about ever, past 12 month and past 30 day (P30D) tobacco use behaviors for combustible-tobacco (cigarettes, traditional cigars, cigarillos, filtered cigars, pipe tobacco, and hookah), ENDS, as well as other non-combustible tobacco (smokeless tobacco, snus pouches, and dissolvable tobacco). At W1, ENDS were described as ‘e-cigarettes that look like regular cigarettes, but are battery-powered and produce vapor instead of smoke’. At Waves 2 through 5, ENDS were described as ‘electronic
nicotine products such as e-cigarettes, e-cigars, e-pipes, e-hookahs, and personal vaporizers, as well as vape pens and hookah pens that are battery-powered, use nicotine fluid rather than tobacco leaves, and produce vapor instead of smoke. Five groups were considered based upon self-reported tobacco use: (1) continuing exclusive combustible-tobacco users (exclusive P30D use of any combustible-tobacco product and no non-combustible-tobacco products) at each wave in an interval (n = 6263 observations); (2) exclusive combustible-tobacco users who transition to exclusive ENDS use (and no other tobacco products, n = 53 observations); (3) exclusive combustible-tobacco users who transition to dual P30D use of ENDS and combustible-tobacco (and no other tobacco products, n = 565 observations); (4) exclusive combustible-tobacco users who quit using tobacco (no P30D use of any tobacco, n = 654 observations); and (5) never users of tobacco who remain P30D non-users of tobacco (n = 3014 observations).

2.1.2. Cardiovascular Risk Factors

In addition to smoking, other established risk factors for CVD include hypertension, elevated cholesterol, diabetes, obesity and family history of CVD [2,3,16,17]. In the PATH Study, adult participants were asked: ‘Has a doctor or other health professional ever told you that you had any of the following conditions?’ Responses included high blood pressure, high cholesterol and diabetes. Participants were also asked, ‘Were any of your close biological or blood relatives ever told by a health professional that they had a heart attack or needed bypass surgery?’ If yes, ‘Were they told they had a heart attack or needed bypass surgery before the age of 50?’ Finally, a body mass index (BMI) was calculated for each participant based on their self-reported height and weight. We limited respondents to those age 40+ years given the very low prevalence of CVD below this age. CVD risk factors included in our analyses are: sex (male), cigarette pack-years, family history of premature heart disease (before age 50), elevated body mass index (BMI) (≥35), and a report of ever having been diagnosed with high blood pressure, high cholesterol, and/or diabetes. These data were collected at each survey wave and used as adjustment variables in regression analysis.

2.1.3. Cardiovascular Outcome Measures

CVD was measured at each wave with a series of questions in which respondents were asked, ‘Has a doctor or other health professional ever told you that you had any of the following conditions?’ Responses included congestive heart failure, stroke, heart attack (also called myocardial infarction (MI)) or needed bypass surgery, some other heart condition, none of the above (yes, no). If respondents reported CHF, stroke, or heart attack at either of the first two waves of an interval, then they were excluded from the analysis. Among the respondents who were free of CVD at the first two waves of an interval, incident cardiovascular conditions were determined at the third wave by asking participants: ‘In the past 12 months, has a doctor or other health professional told you that you had any of the following conditions?’ with the same response options. Participants who reported that they had been told they had CHF, stroke, or heart attack at a subsequent wave were classified as having an incident CVD. Our previous analyses of self-reported CVD among adults age 40 years and older using the PATH Study data established the concurrent validity and reliability of measures of CVD [18].

2.2. Analysis Plan

This study analyzes five waves of PATH Study data, beginning with W1 (2013–2014) through W5 (2018–2019) by considering CVD incidence across three wave intervals: W1 to W3, W2 to W4, and W3 to W5 in a single analysis. The analytic sample was restricted to adults 40 and older with no history of a cardiac condition at either of the first two waves of an interval and who completed all five waves of the PATH Study (n = 7820. For Interval 1 (W1–W3, n = 3562), W1 was the baseline; for Interval 2 (W2–W4, n = 3440, W2 was the baseline; and for Interval 3 (W3–W5, n = 3546), W3 was the baseline. This approach allowed
us to explore number of observations instead of number of participants, resulting in the final sample of 10,548 observations (see Figure 1). Generalized estimating equations (GEE) regression analysis was performed adjusting for CVD risk factors to account for multiple observations for the same individual. This analysis used W5 all-waves weights to obtain statistically valid estimates from longitudinal analyses which examine the PATH Study W1 cohort data across Waves 1 through 5, and variances were estimated using the balanced repeated replication method [19], with Fay’s adjustment set to 0.3 [20].

![Figure 1. Derivation of Analytic Sample.](image)

Change in tobacco use category between the first two waves of a given interval was used to predict onset of CVD between the second and third waves within each interval.

3. Results
3.1. Sample Description

Table 1 presents demographic and cardiovascular risk factors among adults age 40+ years in W1 of the PATH Study by tobacco use category. Among continuing exclusive combustible-tobacco users, 55.3% were male, compared to 47.4% of those who transitioned to exclusive ENDS use, 44.2% of those who transitioned to dual use, 61.7% of those who quit using tobacco, and 32.8% of never users of tobacco (p < 0.001). Of the continuing exclusive combustible-tobacco users, 47.1% were age 55 or over, compared to 43.0% of those who transition to exclusive ENDS use, 33.5% of those who transition to dual use, 50.6% of those who quit using tobacco, and 54.8% of never users of tobacco (p < 0.001). The average number of cigarette pack-years among continuing exclusive combustible-tobacco users was 25.1 years, compared to 16.1 years among those transitioning to exclusive ENDS use, 28.0 years among those transitioning to dual use, and 11.2 years among those who quit using tobacco (p < 0.001). Among continuing exclusive combustible-tobacco users, 11.3% had a BMI ≥ 35, compared to 13.5% of those transitioning to exclusive ENDS use, 13.7% of those transitioning to dual use, 12.4% of those who quit using tobacco, and 14.5% of never users of tobacco (p = 0.01).
Table 1. Selected demographic and cardiovascular risk factors assessed at baseline, PATH Study adults age 40+ with no cardiac condition at baseline, by tobacco user group.

| Exclusive Combustible-Tobacco Users at Baseline | Never Users of Tobacco |
|-----------------------------------------------|------------------------|
| Obs. % SE | Obs. % SE | Obs. % SE | Obs. % SE | Obs. % SE | Obs. % SE | p-value |
|---|---|---|---|---|---|---|
| Sex Male | 3150 | 55.3 | 1.0 | 24 | 47.4 | 7.7 | 223 | 44.2 | 2.2 | 375 | 61.7 | 2.6 | 935 | 32.8 | 1.3 |
| | Female | 3107 | 44.7 | 1.0 | 29 | 52.6 | 7.7 | 341 | 55.8 | 2.2 | 278 | 38.3 | 2.6 | 2067 | 67.2 | 1.3 | <0.001 |
| Age 40–54 | 3403 | 52.9 | 1.2 | 30 | 57.0 | 7.5 | 378 | 66.6 | 2.0 | 353 | 49.4 | 2.8 | 1472 | 45.2 | 1.7 | 0.001 |
| | 55+ | 2860 | 47.1 | 1.2 | 23 | 43.0 | 7.5 | 186 | 33.4 | 2.0 | 301 | 50.6 | 2.8 | 1542 | 54.8 | 1.7 | <0.001 |
| Average Age | 54.6 | 0.2 | 52.2 | 1.6 | 51.5 | 0.4 | 55.7 | 0.5 | 57.6 | 0.5 | 0.001 |
| Average Pack-Years | 25.1 | 0.8 | 16.1 | 2.9 | 28.0 | 2.2 | 11.2 | 1.3 | N/A | 0.001 |
| Ever Report of: | Obs. % SE | Obs. % SE | Obs. % SE | Obs. % SE | Obs. % SE | Obs. % SE |
|---|---|---|---|---|---|---|
| High Blood Pressure (a) | 2510 | 38.4 | 1.2 | 17 | 32.4 | 7.3 | 179 | 30.2 | 2.0 | 252 | 36.2 | 2.5 | 1208 | 39.4 | 1.7 | 0.16 |
| High Cholesterol (a) | 1981 | 32.3 | 0.9 | 18 | 37.2 | 7.4 | 166 | 28.6 | 2.2 | 223 | 38.2 | 2.5 | 940 | 31.1 | 1.5 | 0.10 |
| Diabetes (b) | 1257 | 19.6 | 1.0 | 13 | 24.9 | 6.6 | 110 | 18.0 | 1.9 | 129 | 20.6 | 2.4 | 723 | 23.0 | 1.4 | 0.08 |
| BMI ≥35 (c) | 758 | 11.3 | 0.6 | 8 | 13.5 | 5.0 | 86 | 13.7 | 1.5 | 99 | 12.4 | 1.5 | 495 | 14.5 | 0.9 | 0.01 |
| Family History (d) | 377 | 5.7 | 0.3 | 3 | 4.1 | 2.5 | 50 | 7.7 | 1.1 | 29 | 3.6 | 0.8 | 157 | 5.2 | 0.6 | 0.14 |

Notes: Weighted estimates, unweighted Ns; Baseline, first wave of each interval; Obs., observations; SE, standard error. (a) Has a doctor or other health professional ever told you that you had any of the following conditions? High blood pressure, high cholesterol, congenital heart failure, stroke, and heart attack (no, yes). (b) Has a doctor or other health professional ever told you that you had diabetes? (no, yes). (c) Body mass index (BMI) was calculated for each participant based on their height and weight; elevated BMI was defined as ≥35. (d) Were any of your close biological or blood relatives ever told by a health professional that they had a heart attack or needed bypass surgery? If yes, were they told they had a heart attack or needed bypass surgery before the age of 50? (no, yes). * Estimate has been flagged because it is statistically unreliable. It is based on a denominator sample size of less than 50, or the coefficient of variation of the estimate or its complement is larger than 30 percent.
3.2. Cardiovascular Disease Incidence

Table 2 presents the results of the adjusted GEE regression models. CVD incidence was experienced by 2.1% of continuing exclusive combustible-tobacco users, 0.0% of exclusive combustible-tobacco users who transitioned to exclusive ENDS use, 2.5% of exclusive combustible-tobacco users who transitioned to dual use, 1.6% of exclusive combustible-tobacco users who quit using tobacco and 1.5% of never tobacco users. Since there was no incident CVD among exclusive combustible-tobacco users who transitioned to exclusive ENDS use, that group was not able to be analyzed further. Compared to never users of tobacco, no statistical differences in CVD incidence were observed for continuing exclusive combustible-tobacco users (adjusted odds ratio [AOR] = 1.44; 95% confidence interval (CI) 0.87–2.39), for those who transitioned to dual use (AOR = 1.85; 0.78–4.37), or for those who quit using tobacco (AOR = 1.18; 0.33–4.26). A sensitivity analysis examined frequencies for CVD incidence by cigarette pack-year groupings and found that CVD incidence was higher with more pack-years (results not shown).

Table 2. Cardiovascular disease at follow up by baseline and interim tobacco use status: adjusted GEE results among 9828 observations.

| Baseline Tobacco Use Status | Tobacco Use Status Change | Observations | N with Cardiovascular Disease at Follow Up | % | SE | Adjusted Odds Ratio | Lower | Upper | p-Value |
|----------------------------|---------------------------|--------------|------------------------------------------|---|----|-------------------|-------|-------|---------|
| Exclusive Combustible-Tobacco Users at Baseline | Continuing Exclusive Combustible-Tobacco Use | 6263 | 126 | 2.06 | 0.20 | 1.44 | 0.87 | 2.39 | 0.15 |
| | Switch to ENDS (exclusive use) | 53 | 0 | 0.00 | 0.00 | | | | |
| | Switch to ENDS (dual ENDS/combustible-tobacco use) | 564 | 15 | 2.47 | 0.61 | 1.85 | 0.78 | 4.37 | 0.16 |
| | Quit (no past 30 day tobacco use) | 654 | 10 | 1.55 | 0.78 | 1.18 | 0.33 | 4.26 | 0.80 |
| Never Users of Tobacco | Remain Past 30 Day Non-Users of Tobacco | 3014 | 40 | 1.47 | 0.27 | Ref | | | |

Notes: Weighted estimates, unweighted Ns; Baseline, first wave of each interval; Obs, observations; CVD, cardiovascular disease; SE, standard error; CI, confidence interval. The GEE model is adjusted for sex, age, cigarette pack-years, ever report of high blood pressure or cholesterol, diabetes, BMI ≥ 35, and family history of premature heart disease.

4. Discussion

Previous research has generally reported a 2–4-fold higher risk for CVD among smokers compared to non-smokers [1–3]. A recent study of over 350,000 participants age 35 to 80 in the US, followed for over 10 years, reported a hazard ratio of 1.44 (95% CI 1.38–1.51) for cardiovascular disease among current and former cigarette smokers compared to never combustible-tobacco users [21]. The present study identified a non-statistically significant increased risk for CVD among continuing exclusive combustible-tobacco users compared to never tobacco users (AOR = 1.44; 95% CI 0.87–2.39).

We did not find sufficient evidence to suggest that transitioning to exclusive use of ENDS significantly changes the odds of CVD incidence, although this analysis was based on a small sample size and a relatively limited interval of follow up. We observed no incident CVD among 53 observations of exclusive combustible-tobacco users at a baseline year who transitioned to exclusive ENDS use. This limited number of adults who transitioned from combustible-tobacco to exclusive use of ENDS limits our ability to estimate health effects. Future analyses with additional waves of PATH Study data will increase the statistical power for this comparison. Alternatively, population-based studies may need to oversample exclusive ENDS users to be able to estimate risk accurately. Finally, our overall
findings are consistent with a rapid change in risk of cardiovascular events (e.g., after 3 years of smoking cessation) [5].

Recent publications based on cross-sectional W1 PATH Study data reported lower levels of selected cardiovascular biomarkers (e.g., hs CRP, IL-6, sICAM, fibrinogen, and urinary 8-isoprostane) in exclusive ENDS users compared to exclusive smokers [22] and a greater concentration of 8-isoprostane among dual users of dual cigarettes and e-cigarettes compared to smokers [23]. These biomarkers of inflammation and oxidative stress are associated with smoking-induced CVD, and related biomarkers have been studied as predictive factors for cardiovascular events. In contrast to PATH Study data, others have reported increases in markers of oxidative stress and reduced heart rate variability from ENDS use after acute exposures [9,13].

The obvious limitations of this analysis are its relatively modest sample for several tobacco user groups (especially exclusive ENDS users), relatively young ages of adult smokers who transition to ENDS, and limited duration of follow up. Illustrative of this limitation is an example from the Framingham community study, which, based on the first 4 years of follow up from 1948 to 1950, was unable to show a significant association between smoking and heart disease [24]. It took many more years of observation to reliably establish the association between cigarette smoking and CVD risk [3]. With our study design, we can only identify new cases of CVD that occur within one survey wave of when tobacco use status changes were assessed. Nonetheless, with longer duration of follow up of the PATH Study cohort, future analyses will be able to more reliably assess the association between different patterns of tobacco use and CVD risk as well as the risk of other diseases. Another potential limitation to note is that these findings are based on participants’ self-reported CVD and tobacco use. However, our previous study of CVD among adults age 40 years and older using the PATH Study data established the concurrent validity and reliability of these self-reported measures of CVD [18]. Potential additional analyses might link a measure of biochemical verification of self-reported tobacco use. A final limitation that warrants mention is the use of tobacco products in the past 30 days as the primary measure of tobacco use. There is a wide range of use of tobacco that could classify an individual as a tobacco user, and the PATH Study includes several measures of frequency of use for each tobacco product. However, we determined that past 30 day use was the best measure to use for this analysis in order to include as many observations as possible.

Strengths of this report include the PATH Study data and the use of robust statistical models in the analyses. The use of GEE analyses with “stacked data” over several intervals allowed for the inclusion of observations from three time intervals in a single analysis while statistically controlling for interdependence among observations contributed by the same individual [25,26]. ENDS users tend to be younger than non-users and age adjustment might not eliminate this effect if it is a systematic difference among groups, and data on exposures to marijuana and second hand smoke, physical activity, level of education and medical co-morbidities were not examined. Additionally, based on the tobacco classification definition used, it is possible that persons who used tobacco for limited durations early in adulthood (e.g., ≤10 pack-years) might result in misclassification as former smokers when their risk of incident CVD events is likely much closer to never smokers. Finally, it is also possible that the changes in tobacco use as measured for this analysis were temporary. For example, a sensitivity analysis found that only one-third of those who transitioned to dual use between the first and second waves remained dual users at the third wave, and 16.5% (SE = 2.5) of those who quit between the first and second waves went back to exclusive combustible-tobacco use by the third wave, suggesting the potential for misclassification of tobacco use status. Accordingly, our analytic approach using three wave “windows” likely helped to minimize any misclassification with regard to transient changes in tobacco use status.
5. Conclusions

In conclusion, we did not find evidence to suggest that transitioning to exclusive use of ENDS significantly changes the odds of CVD incidence after one year, although this analysis was based on a limited sample size and a relatively short follow-up interval. These findings are in line with other current research showing that among exclusive combustible-tobacco users who became exclusive ENDS users, CVD incidence does not appear to significantly change [27]. It is possible that additional waves of PATH Study data, combined with information from other large longitudinal cohorts with careful tracking of ENDS use patterns, may help to further clarify this relationship.

Author Contributions: Conceptualization, M.C.M. and A.H.; methodology, A.H.; validation, E.S., M.J.H.; formal analysis, C.R.; resources, A.H.; data curation, C.A.S.; writing—original draft preparation, M.C.M. and C.R.; writing—review and editing, H.T.H., J.S., K.M.C., R.N., M.L.G., M.B.-T., D.H., D.G., G.F., S.G., C.H.C., R.H., M.L.S., C.B. and W.C.; supervision, C.A.S.; project administration, H.L.K.; funding acquisition, A.H. All authors have read and agreed to the published version of the manuscript.

Funding: This manuscript is supported with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, and the Center for Tobacco Products, Food and Drug Administration (FDA), Department of Health and Human Services, under contract to Westat (Contract Nos. HHSN271201100027C and HHSN27120160000IC).

Institutional Review Board Statement: This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Westat.

Informed Consent Statement: Informed consent was obtained from all subjects involved in this study.

Data Availability Statement: Restricted data sets were analyzed in this study and the data is not publicly available. Since restricted use files (RUFs) retain more than minimal risk for reidentification of a research subject, access to RUFs is granted through controlled conditions to vetted researchers and sponsor-supervised students.

Conflicts of Interest: Wilson Compton reports long-term stock holdings in General Electric, 3M Company, and Pfizer Incorporated, unrelated to this article. K. Michael Cummings provides expert testimony on the health effects of smoking and tobacco industry tactics in lawsuits filed against the tobacco industry. He has also received payment as a consultant to Pfizer, Inc., for services on an external advisory panel to assess ways to improve smoking cessation delivery in health care settings. Martin C. Mahoney has provided expert testimony on the health effects of smoking in lawsuits filed against the tobacco industry. He has also received research support from Pfizer, Inc., for an on-going clinical trial of smoking cessation, and has previously served on external advisory panels sponsored by Pfizer to promote smoking cessation in clinical settings. Geoff Fong has a Senior Investigator Award from the Ontario Institute for Cancer Research and a Prevention Scientist Award from the Canadian Cancer Society Research Institute. Maciej Goniewicz has received a research grant from Pfizer and served as a member of a scientific advisory board to Johnson & Johnson. Raymond Niura receives funding from the Food and Drug Administration Center for Tobacco Products via contractual mechanisms with Westat and the National Institutes of Health. Within the past 3 years, he has served as a paid consultant to the Government of Canada via a contract with Industrial Economics Inc., has received an honorarium for a virtual meeting from Pfizer Inc., and has served as an uncompensated grant reviewer for foundation for smoke free world during the time he was working on this paper.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Department of Health and Human Services or any of its affiliated institutions or agencies.

References
1. Public Health Service. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service; Government Printing Office: Washington, DC, USA, 1964.
2. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General; US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2014.
3. Castelli, W.P. Epidemiology of coronary heart disease: The Framingham study. Am. J. Med. 1984, 76, 4–12. [CrossRef]
4. Heron, M. Deaths: Leading Causes for 2017. In National Vital Statistics Reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System; National Center for Health Statistics: Hyattsville, MD, USA, 2019; Volume 68, pp. 1–77.

5. Prochaska, J.J.; Benowitz, N.L. Smoking cessation and the cardiovascular patient. Curr. Opin. Cardiol. 2015, 30, 506–511. [CrossRef] [PubMed]

6. Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion; Office on Smoking and Health. Publications and Reports of the Surgeon General. In How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2010.

7. Farsalinos, K.E.; Tsiaras, D.; Kyrzopoulos, S.; Savvopoulou, M.; Voudris, V. Acute effects of using an electronic nicotine-delivery device (electronic cigarette) on myocardial function: Comparison with the effects of regular cigarettes. BMC Cardiovasc. Disord. 2014, 14, 78. [CrossRef] [PubMed]

8. Yan, X.S.; D'Ruiz, C. Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Regul. Toxicol. Pharmacol. RTP 2015, 71, 24–34. [CrossRef]

9. Carnevale, R.; Sciarretta, S.; Violi, F.; Nocella, C.; Loffredo, L.; Perri, L.; Peruzzi, M.; Marullo, A.G.M.; Falco, E.D.; Chimenti, I.; et al. Acute Impact of Tobacco vs Electronic Cigarette Smoking on Oxidative Stress and Vascular Function. Chest 2016, 150, 606–612. [CrossRef]

10. Hartmann-Boyce, J.; McRobbie, H.; Bullen, C.; Beigh, R.; Stead, L.F.; Hajek, P. Electronic cigarettes for smoking cessation. Cochrane Database Syst. Rev. 2016, 9, CD010216. [CrossRef]

11. Hyland, A.; Ambrose, B.K.; Conway, K.P.; Borek, N.; Lambert, E.; Carusi, C.; Tayloret, K.; Crosse, C.; Fong, G.T.; Cummings, K.M.; et al. Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tob. Control 2017, 26, 371–378. [CrossRef]

12. Population Assessment of Tobacco and Health (PATH) Study [United States] Restricted-Use Files; Restricted Use Files User Guide. Available online: https://doi.org/10.3886/Series606 (accessed on 30 March 2022).

13. Prochaska, J.J.; Benowitz, N.L. Smoking cessation and the cardiovascular patient. Curr. Opin. Cardiol. 2015, 30, 506–511. [CrossRef] [PubMed]

14. Hyland, A.; Ambrose, B.K.; Conway, K.P.; Borek, N.; Lambert, E.; Carusi, C.; Tayloret, K.; Crosse, C.; Fong, G.T.; Cummings, K.M.; et al. Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tob. Control 2017, 26, 371–378. [CrossRef]

15. Judkins, D.R. Fay’s method for variance estimation. J. Off. Stat. 1990, 6, 223–239. [CrossRef]

16. Mahoney, M.C.; Rivard, C.; Hammad, H.T.; Blanco, C.; Sargent, J.; Kimmel, H.L.; Wang, B.; Halenar, M.J.; Kang, J.C.; Borek, N.; et al. Cardiovascular Risk Factor and Disease Measures from the Population Assessment of Tobacco and Health (PATH) Study. Int. J. Environ. Res. Public Health 2021, 18, 7692. [CrossRef]

17. McCarthy, P.J. Pseudoreplication: Further Evaluation and Applications of the Balanced Half-Sample Technique; Vital Health Stat 2; US Health Services and Mental Health Administration: Rockville, MD, USA, 1969; Volume 31, pp. 1–24, PMID: 5306564.

18. Judkins, D.R. Fay’s method for variance estimation. J. Off. Stat. 1990, 6, 223–239. [CrossRef]

19. Christensen, C.H.; Rostron, B.; Cosgrove, C.; Altekruse, S.F.; Hartman, A.M.; Gibson, J.T.; Apelberg, B.; Inoue-Choi, M.; Freedman, N.D. Association of Cigarette and Electronic Cigarette Use Patterns with Levels of Inflammatory and Oxidative Stress Biomarkers Among US Adults: Population Assessment of Tobacco and Health Study. Circulation 2021, 143, 869–871. [CrossRef]

20. Stokes, A.C.; Xie, W.; Wilson, A.E.; Yang, H.; Orimoloye, O.A.; Harlow, A.F.; Fettermen, J.L.; DeFilippis, A.P.; Benjamin, E.J.; Robertson, R.M.; et al. Association of Cigarette and Electronic Cigarette Use Patterns with Levels of Inflammatory and Oxidative Stress Biomarkers Among US Adults: Population Assessment of Tobacco and Health Study. Circulation 2021, 143, 869–871. [CrossRef]

21. Christensen, C.H.; Chang, J.T.; Rostron, B.L.; Hammad, H.T.; Bemmel, D.M.v.; Valle-Pinero, A.Y.D.; Wang, B.; Mishina, E.V.; Faulcon, L.M.; DePina, A.; et al. Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Users-Results from Wave 1 PATH Study. Cancer Epidemiol. Biomark. Prev. 2021, 30, 1947–1955. [CrossRef]

22. Dawber, T.R.; Moore, F.E.; Mann, G.V. Coronary heart disease in the Framingham study. Circulation 1986, 73, 13–22. [CrossRef]

23. Liang, K.-Y.; Zeger, S.L. Longitudial data analysis using generalized linear models. Biometrika 1986, 73, 13–22. [CrossRef]

24. Hardin, J.W. Generalized estimating equations (GEE). Encycl. Stat. Behav. Sci. 2005, 2, 721–729.

25. Goniewicz, M.L.; Miller, C.R.; Sutanto, E.; Li, D. How effective are electronic cigarettes for reducing respiratory and cardiovascular risk in smokers? A systematic review. Harm. Reduct. J. 2020, 17, 91. [CrossRef] [PubMed]